Navigation Links
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Date:3/31/2008

apies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and CETHRIN, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
4. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Replikins Ltd. today released new ... Ebola virus. Before the current outbreaks, the mean Ebola ... amino acids) between 1995 and 2002 was 1.1; the ... 2012, and sixteen-fold in 2013, thus predicting the current ... technology has been shown to be able to predict ...
(Date:7/30/2014)... July 30, 2014 Sales Horizons, a ... of blended sales training programs for companies engaged in ... programs used by thousands of salespeople over 25 years ... training program can be customized to address the unique ... blended sales training program consists of two ...
(Date:7/30/2014)... BROOK, NY (PRWEB) July 30, 2014 ... APDN), (Twitter: @APDN), a biotechnology firm that provides DNA-based ... Michael E. Hogan, Ph.D. Vice President of Life Sciences, ... mid-September. , Dr. Hogan will lead APDN’s ... form business relationships with biotech and healthcare customers, provide ...
(Date:7/30/2014)... Yuma, AZ (PRWEB) July 30, 2014 ... , State-of-the-art facility and complementary therapies brings comprehensive ... square foot, state-of-the-art Yuma Regional Cancer Center has ... since 2012, the program includes services such as ... laboratory, massage therapy, American Cancer Society Resource Center, ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... victory for its client,Applera Corporation, a global leader in ... summary judgment ruling invalidating three key,contested life sciences patents. ... DNA sequencing reagents and instruments infringed,the patents in question. ... Bond Arterton of the,United States District Court for the ...
... a civil settlement with the U.S. Department of ... the federal False Claims Act,relating to Anzemet(R) involving ... The settlement relates to government claims that ... turn increased the cost of,government reimbursements for the ...
... 10 BioStorage Technologies, Inc.,(BST) announced that it ... Company (IPL) to purchase electricity generated by 100 ... voluntary,program. By offsetting the use of fossil-fueled power ... completely carbon-neutral by 2009. BST becomes the ...
Cached Biology Technology:Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents 2BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 2BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 3BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy 4
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... analysis of the roughly 3,000 pieces is still in ... the results will be of major significance. "Amazingly often, ... species in Fushun amber that we found in Baltic ... , The Baltic amber comes from the Baltic Sea ... rich in finds are, e.g., the coastal regions of ...
(Date:7/30/2014)... Washington, DCToday scientists unveiled the first high-resolution map ... the entire country of Per. The new and ... a sea change for future market-based carbon economies. ... extremely high ecological diversity and it provides the ... degradation for conservation, land use, and enforcement purposes. ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... Deborah A. Frank, MD, the Director of the Grow ... a Professor of Pediatrics at Boston University School of ... from the National Institutes of Health to study the ... substance exposure (IUSE). The project, entitled Prenatal ...
... , Researchers at Yale School of Medicine have found ... type leads to Type 1 Gaucher disease, a rare ... in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, ... The new findings could lead to less expensive ...
... This release is available in French . , ... Neuro, McGill University have discovered that our brains have the ... processing specially-coded sounds, without any visual or tactile input. Not ... of the brain and how it perceives the world around ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2See no shape, touch no shape, hear a shape? 2
...
... Western Blot Strong Antibody Stripping Solution is ... blots that have been developed with chemiluminescence ... is not recommended for stripping colorimetric substrates ... not possible to effectively remove substrates that ...
... Liquid. 100 ml supplied as a ... remove antibodies from membrane-bound proteins without ... stripping chemiluminescent or radioisotopic signals from ... Western blots. Supplied as a 5X ...
... is specifically designed for two-dimensional electrophoresis ... four proteins in this marker have ... pattern across a 2D gel. The ... Mol wt: 17,000-89,000 ...
Biology Products: